Coordinating Your Care and Treatment
At a Glance
BBS9 care is a coordinated, lifelong plan involving genetics, kidney, eye, endocrine, nutrition, psychology, and low-vision specialists. Setmelanotide may help eligible people with BBS-associated obesity, while vision rehabilitation and structured routines support safety and independence.
Managing Bardet-Biedl Syndrome type 9 (BBS9) requires more than just treating individual symptoms; it requires a coordinated, lifelong partnership between you and a team of specialists [1]. Because BBS9 affects multiple systems, “multidisciplinary care” means that your doctors—from the kidney specialist to the eye doctor—work together to see your health holistically [2].
Building Your Multidisciplinary Team
International guidelines recommend that care be delivered by professionals who understand the unique challenges of ciliopathies [1][3]. Your core team will likely include:
- Clinical Geneticist: To interpret the BBS9 variants and provide family counseling [4].
- Nephrologist: To monitor kidney function and blood pressure [5].
- Ophthalmologist: Ideally one specializing in inherited retinal diseases, to manage vision changes [6].
- Endocrinologist: To manage weight, growth, diabetes screening, and pubertal development [7].
- Dietitian and Psychologist: To support healthy nutrition and help manage the emotional impact of hyperphagia (the biological hunger drive) [8][9].
- Low-Vision Specialists: To provide tools and training for navigating the world as vision changes [4].
Targeted Treatment for Obesity: Setmelanotide
For many years, managing weight in BBS relied solely on diet and exercise, which can be incredibly difficult due to the biological hunger drive. Recently, a medication called setmelanotide was approved in various jurisdictions for eligible patients with BBS-associated syndromic obesity [10].
- How it works: It is an MC4R agonist, meaning it acts on pathways in the brain involved in feeling full [11]. It does not cure retinal disease or kidney disease.
- Efficacy: In a 52-week clinical trial, 32.3% of participants aged 12 and older with BBS achieved at least a 10% weight loss [12]. Responses vary, and a propensity-matched external control analysis observed significant BMI reduction in a larger share of treated patients compared to controls [10].
- Important Safety Information: The medication is a daily injection under the skin [12]. Common side effects include skin hyperpigmentation (darkening of the skin or existing nevi/moles), injection site reactions, and nausea/vomiting [13][14]. Crucially, monitoring for depression and suicidal ideation is required, as well as evaluating any sexual adverse effects or pregnancy-related guidance per the prescribing label [11]. Access and eligibility depend on local regulations.
Supporting Vision and Mobility
Because there is currently no cure to reverse the breakdown of the retina, “treatment” for vision focuses on rehabilitation and independence [6].
- Low-Vision Aids: This includes high-contrast materials, magnifiers, and specialized software [4].
- Orientation and Mobility (O&M): This is specialized training that teaches safe navigation, including the use of a white cane [1]. Starting this early helps build confidence for the future.
- Educational/Workplace Support: Work to create a local individualized education or disability-support plan (such as an IEP in the U.S.) that accounts for progressive vision loss and any learning or behavioral differences [1].
Preparing for Specialist Visits
To get the most out of your multidisciplinary appointments, it helps to arrive organized:
- Keep a “Symptom Log”: Note any changes in appetite, night vision, or bathroom habits since the last visit.
- Track the “Growth Curve”: Bring a copy of height, weight, and blood pressure history.
- Request a “Summary Letter”: Ask each specialist to send a note to your primary care doctor and your “lead” coordinator to keep everyone on the same page.
While new treatments are beneficial for some, foundational lifestyle measures—like consistent routines and structured, non-shaming meal times—remain the “bedrock” of care [15][1].
Common questions in this guide
Which specialists are usually involved in BBS9 care?
What does setmelanotide do for people with BBS9?
What should be monitored if setmelanotide is started?
How can treatment support vision and independence in BBS9?
How should we prepare for BBS9 specialist appointments?
What daily strategies can help with BBS9-related hyperphagia?
Get notified when new evidence is published on BBS9-related ciliopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations.
Dollfus H, Lilien MR, Maffei P, et al.
European journal of human genetics : EJHG 2024; (32(11)):1347-1360 doi:10.1038/s41431-024-01634-7.
PMID: 39085583 - 2
Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management.
Shoemaker A
Diabetes, obesity & metabolism 2024; (26 Suppl 2()):25-33 doi:10.1111/dom.15494.
PMID: 38383825 - 3
Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria.
Pomeroy JJ, Richards J, Sweeney BR, et al.
American journal of medical genetics. Part A 2026; (200(10)):2181-2198 doi:10.1002/ajmg.a.70199.
PMID: 42175648 - 4
[The Bardet-Biedl Syndrome - Diagnosis and Follow-up].
Rohrschneider K, Bolz HJ
Klinische Monatsblatter fur Augenheilkunde 2020; (237(3)):239-247 doi:10.1055/a-1118-3748.
PMID: 32182628 - 5
Assessment of Renal Changes in Bardet-Biedl Syndrome with Particular Emphasis on Kidney Size, Function, and Blood Pressure Control.
Moskal Z, Szmigielska A
Journal of mother and child 2026; (30(1)):123-128 doi:10.34763/jmotherandchild.20263001.d-26-00009.
PMID: 42370448 - 6
Ophthalmologic Manifestations in Bardet-Biedl Syndrome: Emerging Therapeutic Approaches.
Rosado A, Rodriguez E, Izquierdo N
Medicina (Kaunas, Lithuania) 2025; (61(7)) doi:10.3390/medicina61071135.
PMID: 40731764 - 7
[Improved Care and Treatment Options for Patients with Hyperphagia-Associated Obesity in Bardet-Biedl Syndrome].
Cetiner M, Bergmann C, Bettendorf M, et al.
Klinische Padiatrie 2024; (236(5)):269-279 doi:10.1055/a-2251-5382.
PMID: 38458231 - 8
Hyperphagia in Bardet-Biedl syndrome: Pathophysiology, burden, and management.
Beales PL, Cetiner M, Haqq AM, et al.
Obesity reviews : an official journal of the International Association for the Study of Obesity 2025; (26(7)):e13915 doi:10.1111/obr.13915.
PMID: 40186386 - 9
Incidental diagnosis of Bardet-Biedl syndrome in a case of abdominal tuberculosis: a case report.
Andanappa A, Alla SSM, Malireddi A, et al.
Journal of medical case reports 2025; (19(1)):402 doi:10.1186/s13256-025-05455-0.
PMID: 40790500 - 10
Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Argente J, Haqq AM, Schorfheide JL, et al.
Obesity (Silver Spring, Md.) 2026; (34(3)):579-587 doi:10.1002/oby.70125.
PMID: 41703984 - 11
An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
Lazareva J, Brady SM, Yanovski JA
Expert opinion on pharmacotherapy 2023; (24(6)):667-674 doi:10.1080/14656566.2023.2199152.
PMID: 37013719 - 12
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM, Chung WK, Dollfus H, et al.
The lancet. Diabetes & endocrinology 2022; (10(12)):859-868 doi:10.1016/S2213-8587(22)00277-7.
PMID: 36356613 - 13
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.
Sridharan K, Sivaramakrishnan G
Expert opinion on drug safety 2026; (25(8)):1507-1516 doi:10.1080/14740338.2025.2465880.
PMID: 39924461 - 14
Setmelanotide in Bardet-Biedl Syndrome: A Case Report.
Smith S, Sanfilippo E, Lee LW
Pediatric dermatology 2026; (43(5)):1196-1199 doi:10.1111/pde.70186.
PMID: 41994885 - 15
Obesity in Children Aged 2 to 12 Years: A Review.
Fox CK, Armstrong SC, Kelly AS
JAMA 2026; doi:10.1001/jama.2026.18806.
PMID: 42905688
This page provides information about coordinating BBS9 care and treatment for educational purposes only and does not constitute medical advice. Discuss setmelanotide, monitoring, and accommodations with your healthcare team.